Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | XPO1 | O14980 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288587 | 0.92 | GRM7 (0.44) | GRM7TP53MAPTNPC1 | |
| SCHEMBL6288552 | 0.86 | GRM7 (0.38) | GRM7S1PR1HRH4XPO1TP53 | |
| SCHEMBL6288630 | 0.86 | S1PR1 (0.38) | GRM7S1PR1HRH4XPO1MAPT | |
| SCHEMBL6291459 | 0.85 | S1PR1 (0.37) | GRM7S1PR1HRH4XPO1TP53 | |
| SCHEMBL6288657 | 0.83 | SMN1; SMN2 (0.42) | TP53MAPTNPC1KMT2A | |
| SCHEMBL6291399 | 0.81 | POLB (0.37) | TP53MAPTMEN1NPC1KMT2A | |
| SCHEMBL6288381 | 0.81 | LMNA (0.34) | TP53MAPTGSK3BKCNJ5KCNJ3 | |
| SCHEMBL6291832 | 0.80 | GRM7 (0.41) | GRM7TP53MAPTNPC1 | |
| SCHEMBL6291757 | 0.80 | GRM7 (0.41) | GRM7MAPTMEN1KMT2A | |
| SCHEMBL5916392 | 0.80 | PDE2A (0.36) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936609-B2 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249148-A1 | Imidazotriazines for use as phosphodiesterase inhibitors | PDE3A, PDE2A, PDE4A | GRM7 2512/4885S1PR1 2809/4885HRH4 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.